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BJNhem20-OCIAD1-CRISPR-39 line heterozygous knockout for
OCIAD1was generated by targeting exon3 of OCIAD1 using CRISPR-Cas9
mediated knockout strategy (Fig. 1A). The method is based on an earlier
report (Peters et al., 2013). BJNhem20 cells were co-transfected with
pCas9D10A-GFP and OCIAD1 sgRNA expression constructs targeting two
sites on exon3 for double nickase activity. Cas9D10A-GFP expressing
cells were sorted and plated clonally on mTESR containing Matrigel-
coated dishes. Forty individual colonies were picked and expanded for
screening. Genomic DNA was isolated and screened by high fidelity PCR
amplification followed by sequencing of exon3 of OCIAD1 at the targeted
region. Seven heterozygous knockouts were obtained and one of them is
BJNhem20-OCIAD1-CRISPR-39, which was characterized further.
OCIAD1 depletion was validated by immunostaining and Western
blot analysis for OCIAD1 levels, in three biological replicates.
Expression of pluripotent stem cell markers OCT4, SSEA3/4, and
TRA1-81 has been shown by immunostaining. Differentiation of these
hESC lines to all the three germ layers was demonstrated by immuno-
staining for markers such as AFP (endoderm), Brachyury (mesoderm)
and β-III tubulin (ectoderm). Karyotype was also checked in these
cells and found to be normal.
Materials and methods
Cell culture
hESC line-BJNhem20 was derived from the discarded Grade III em-
bryos and tested for its pluripotency (Inamdar et al., 2009). This cell
line has been cultured continuously for over 200 passages without ac-
quiring karyotypic abnormality (Venu et al., 2010).The cell line was in-
cluded in the analysis of genetic stability in the International Stem Cellthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) Strategy for targeting OCIAD1 exon3 by CRISPR-CAS9. (B) Genomic targeting of OCIAD1 exon3 of BJNhem20-OCIAD1-CRISPR-39 identified by T7 endonuclease mediated
digestion of high fidelity exon 3 amplicon detecting deletions in this clone. (C) Chromatograms showing sequence analysis to confirm heterozygous mutation in the targeted region of
OCIAD1. (D) Western blot analysis showing decreased OCIAD1 levels in BJNhem20-OCIAD1-CRISPR-39. Graph represents standard error mean after analysis of three biological
replicates using single factor ANOVA (P value 0.001). (E) Karyotype analysis of BJNhem20-OCIAD1-CRISPR-39. (F) Analysis of transcript levels of pluripotency marker genes Oct4,
Nanog, TDGF and Sox2 by reverse transcription and polymerase chain reaction (RT-PCR) amplification. GAPDH was used to normalize transcript levels. (G) Immunostaining analysis of
BJNhem20-OCIAD1-CRISPR-39 for depletion of OCIAD1 and for pluripotency markers Oct4, SSEA4 and TRA1-81 as indicated, compared to parental hESC line BJNhem20.
(H) Differentiation analysis of BJNhem20-OCIAD1-CRIPSR-39: embryoid bodies stained to show differentiation to all the three germ layers by immunostaining for AFP, Brachyury and
β-III tubulin marking the endoderm, mesoderm and ectoderm respectively.
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ic line BJNhem20-OCIAD1-CRISPR-39 were maintained on mouse
embryonic fibroblast feeder layers in hESC medium composed of
KnockOut Dulbecco's modified Eaglemedium (KO-DMEM-Life Technolo-
gies Cat no. 10829-018) supplemented with 20% KnockOut Serum
replacement (KOSR-Life Technologies Cat no. 10828-028), 1% GlutaMAX
(Life Technologies Cat no. 35050-061), 1% non-essential amino
acids (MEM-NEAA-Life Technologies Cat no. 11140-050), 0.1% β-
mercaptoethanol (Life Technologies Cat no. 21985-023) and 8 ng/ml
human recombinant basic fibroblast growth factor (human bFGF-Sigma
Aldrich Pvt. Ltd. Cat no. F-0291).These cells were routinely passaged by
mechanical cutting of undifferentiated colonies.
Electroporation of hESCs to generate BJNhem20-OCIAD1-CRISPR-39 cell
line
For electroporation, BJNhem20cells were grown on Matrigel-coated
(Becton Dickinson Cat. No. 354277) dishes in mTESR medium (Stem
Cell Technologies Cat. No. 05850), until the culture was 80% confluent.To aid survival of single cells post transfection the cultures were pre-
treated with ROCK inhibitor (10 μM Y-27632, Sigma Aldrich) for 3 h
prior to electroporation. The cells were trypsinized using 1X TrypLE
(Life Technologies Cat. No. 12605010) at 37 °C for 4 min. The cells
were pelleted by centrifugation at 1000 rpm for 2 min, washed with
phosphate buffered saline and enumerated. 1 million cells were resus-
pended in 400 μl cold OptiMEM medium and mixed with plasmids
pCAS9-D10A-GFP (Addgene ID 44720) 5 μg, OCIAD1 CRISPR Left and
Right Exon3 targeting sgRNA expression constructs (Custom generated
by Genocopoeia) 2.5 μg each. Electroporationwas performed in a 0.4 cm
Biorad electroporation cuvette at 250mV, 500 μF for 10ms. Immediate-
ly after electroporation 0.5 ml of cold mTESR1 medium was added
and the cells were transferred to a 15 ml centrifugation tube and
spun down at 1000 rpm for 2 min. The cells were resuspended in
“post-FACS recovery media” which was made using pre-conditioned
mTESR and fresh mTESR1 (1:1), 8 ng/ml bFGF, supplemented with
ROCK inhibitor (10 μMY-27632) and seeded onMatrigel-coated dishes.
16 h after electroporation the medium was replaced with mTESR1 me-
dium without ROCK inhibitor.
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GFP expression was monitored 48 h post transfection and after 72 h
cells were harvested as mentioned above for sorting GFP+ population.
The cells were resuspended in cold OptiMEM, passed through a 40 μm
pore size cell strainer and then sorted for GFP expression using BD
FACS ARIA II cell sorter. Sorted cells were collected in 15 ml centrifuge
tubes containing 5 ml of OptiMEM with Antibiotic–Antimycotic
(Life technologies Cat no. 15240-062). Post-sort the cells were incubat-
ed at 4 °C for 10 min, pelleted by centrifugation at 1000 rpm for 2 min
and resuspended in 2 ml of post-FACS recovery medium. 200 GFP posi-
tive cells were seeded in 35 mm Matrigel-coated dish in post-FACS
recovery medium with 10 μM ROCK inhibitor and 1X Antibiotic–
Antimycotic Medium was replaced with fresh post-FACS recovery
medium (without ROCK inhibitor) every 24 h.
Screening of BJNhem20OCIAD1-CRISPR and Cas9D10A transfected cultures
to generate BJNhem20-OCIAD1-CRISPR-39 cell line
Four days after FACS sorting, undifferentiated hESC colonies were
clearly visible and cultures were switched to regular mTESR medium.
Colonies were picked on day 8 and seeded individually on Matrigel-
coatedwells of 24well plate for clonal expansion. After passaging to ob-
tain duplicates, a single well of each clone was harvested and screened
for in-del mutations as described before (Peters et al., 2013). Briefly,
genomic DNA was isolated and PCR amplified using high-fidelity
DNA polymerase (KAPA HiFi) and primers spanning OCIAD1 exon3
(OCIAD1 Intron2F: 5′gggtgcctcttgttaatgtttaggc3′; OCIAD1 Intron3R: 5′
cagacagacctgttttcaactcca3′), followed by PCR Cleanup (Machery Nagel
Kit), sequencing (Sanger's Sequencing) and in-del detection using
T7endonuclease (New England Biolabs) for the digestion of high-
fidelity PCR amplicon (Fig. 1B).
Embryoid body differentiation
Differentiation of embryoid bodies was carried out as described be-
fore (Inamdar et al., 2009). Briefly, colonies grown on MEFs were me-
chanically cut and pieces cultured in human embryoid body media
(10% FBS-Hyclone-SH30070 with β-mercaptoethanol and GlutaMAX
in DMEM) on low attachment plates. These hESC aggregates were
allowed to grow in suspension for 3 days after which the colonies
formed embryoid body-like structures and were transferred to tissue
culture dishes pre-treated with 0.1% gelatin and allowed to attach and
differentiate spontaneously till the time for harvest for immunostaining
analyses.
Immunostaining
hESC and hEBs were fixed in 2% paraformaldehyde (in PBS), perme-
abilized with Triton-X 100 (0.1% for cells and 0.3% for EBs) and then
blocked with 4% FBS for 1 h at RT (Room Temperature). Post blocking,
cells were incubatedwith the appropriate primary antibodies overnight
at 4 °C, washed with PBS at RT and incubated with secondary antibody
conjugated to either Alexa Fluor 488 or 568 for 1 h at RT (Dilution 1:400Invitrogen).The cells were washed and stained using DAPI (1:500 inM1
buffer Invitrogen) to visualize nuclei. The images were acquired using
an epifluorescence microscope (IX-81(Olympus)) fitted with a cooled
CCD camera (CoolSnap, Roper Scientific). Primary antibodies used
were against OCIAD1 (Abcam Ab91574), Oct4 (BD Biosciences
BD611203), TRA1-81 and SSEA4 (kind gift from Peter Andrews, Univer-
sity of Sheffield, UK), Brachyury (Santa Cruz Biotech Cat no. SC-17743),
β-III tubulin (Santacruz SC-51670), AFP (Sigma Chemical Pvt. Ltd. Cat
no. A8452).
RNA isolation, cDNA synthesis and PCR
Total RNA was extracted from cells using TRIzol reagent (Life
Technologies Cat no. 15596-026) following the manufacturer's instruc-
tions. 2 μg of DNase treated RNAwas converted to cDNA by performing
reverse transcription using Superscript II (Life Technologies Cat no.
18064-014). Primer sequences used for cDNA amplification (5′–3′)
were as follows:.rimer name Sequence
ct4_F gaaggtattcagccaaacgac
ct4_R gttacagaaccacactcgga
anog_F tgcaaatgtcttctgctgagat
anog_R gttcaggatgttggagagttc
pdh_F gtccatgccatcactgcca
pdh_R ttactccttggagccatg
gf_F tccttctacggacggaactg
gf_R agaaatgcctgaggaaagcatdVerification of karyotype
Standard G banding of metaphase spreads was performed and ana-
lyzed using CytoVision software. For each sample, at least 50 meta-
phases were counted and 10 were analyzed.
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